Abstract
Autologous haematopoietic stem-cell transplantation has been evaluated over the last years as a possible new therapeutic strategy in severe forms of multiple sclerosis unresponsive to the approved therapies. Up to now, more than 400 patients have been treated and numerous are the phase I and phase II studies which addressed the feasibility of this treatment, the efficacy, side effects and transplant-related mortality. The clinical response is strongly related to the intensity of the conditioning regimen utilized as well as to the phase of the disease course in which the therapy is carried out. Rapidly evolving multiple sclerosis with a relapsing-remitting clinical course and MRI signs of activity are the cases that can take more advantage. The risk of mortality, which dropped in the last years to 2-3%, is still the main problem of this powerful therapy.
| Original language | English |
|---|---|
| Journal | Neurological Sciences |
| Volume | 30 |
| Issue number | SUPPL. 2 |
| DOIs | |
| Publication status | Published - 2009 |
Fingerprint
Keywords
- Autologous stem-cell transplantation
- Intense immunosuppression in multiple sclerosis
- Malignant forms of multiple sclerosis
- Multiple sclerosis
ASJC Scopus subject areas
- Clinical Neurology
- Psychiatry and Mental health
- Dermatology
Cite this
Autologous haematopoietic stem-cell transplantation in multiple sclerosis : Benefits and risks. / Capello, E.; Vuolo, L.; Gualandi, F.; Van Lint, M. T.; Roccatagliata, L.; Bonzano, L.; Pardini, M.; Uccelli, A.; Mancardi, Gianluigi.
In: Neurological Sciences, Vol. 30, No. SUPPL. 2, 2009.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Autologous haematopoietic stem-cell transplantation in multiple sclerosis
T2 - Benefits and risks
AU - Capello, E.
AU - Vuolo, L.
AU - Gualandi, F.
AU - Van Lint, M. T.
AU - Roccatagliata, L.
AU - Bonzano, L.
AU - Pardini, M.
AU - Uccelli, A.
AU - Mancardi, Gianluigi
PY - 2009
Y1 - 2009
N2 - Autologous haematopoietic stem-cell transplantation has been evaluated over the last years as a possible new therapeutic strategy in severe forms of multiple sclerosis unresponsive to the approved therapies. Up to now, more than 400 patients have been treated and numerous are the phase I and phase II studies which addressed the feasibility of this treatment, the efficacy, side effects and transplant-related mortality. The clinical response is strongly related to the intensity of the conditioning regimen utilized as well as to the phase of the disease course in which the therapy is carried out. Rapidly evolving multiple sclerosis with a relapsing-remitting clinical course and MRI signs of activity are the cases that can take more advantage. The risk of mortality, which dropped in the last years to 2-3%, is still the main problem of this powerful therapy.
AB - Autologous haematopoietic stem-cell transplantation has been evaluated over the last years as a possible new therapeutic strategy in severe forms of multiple sclerosis unresponsive to the approved therapies. Up to now, more than 400 patients have been treated and numerous are the phase I and phase II studies which addressed the feasibility of this treatment, the efficacy, side effects and transplant-related mortality. The clinical response is strongly related to the intensity of the conditioning regimen utilized as well as to the phase of the disease course in which the therapy is carried out. Rapidly evolving multiple sclerosis with a relapsing-remitting clinical course and MRI signs of activity are the cases that can take more advantage. The risk of mortality, which dropped in the last years to 2-3%, is still the main problem of this powerful therapy.
KW - Autologous stem-cell transplantation
KW - Intense immunosuppression in multiple sclerosis
KW - Malignant forms of multiple sclerosis
KW - Multiple sclerosis
UR - http://www.scopus.com/inward/record.url?scp=74049122036&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=74049122036&partnerID=8YFLogxK
U2 - 10.1007/s10072-009-0144-5
DO - 10.1007/s10072-009-0144-5
M3 - Article
C2 - 19882370
AN - SCOPUS:74049122036
VL - 30
JO - Neurological Sciences
JF - Neurological Sciences
SN - 1590-1874
IS - SUPPL. 2
ER -